Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -266.86% is 20% above its 4-year average of -334.28%, around the middle of its 4-year range (-749.08%–-25.88%).
As of the fiscal period ended Tuesday, June 30, 2026. 42.14% below its 12-month average of -187.75%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -266.86%.
RETURN ON EQUITY (ROE)
-266.86%
RETURN ON EQUITY (ROE) AVG TTM
-187.75%
RETURN ON EQUITY (ROE) AVG 3Y
-267.71%
RETURN ON EQUITY (ROE) AVG 5Y
-334.28%
RETURN ON EQUITY (ROE) AVG 10Y
-212.31%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-42.14%
CURRENT VS 3Y AVG
+0.32%
CURRENT VS 5Y AVG
+20.17%
CURRENT VS 10Y AVG
-25.70%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-535.23%
vs the sector median at left
LifeMD, Inc.
Market Cap
$159.22M
Return on Equity (ROE)
-266.86%
TTM Avg
-187.75%
3Y Avg
-267.71%
5Y Avg
-334.28%
Market Cap
$159.78M
Return on Equity (ROE)
-60.19%
TTM Avg
-68.34%
3Y Avg
-61.91%
5Y Avg
-47.91%
Market Cap
$159.14M
Return on Equity (ROE)
-215.26%
TTM Avg
-150.35%
3Y Avg
8.65%
5Y Avg
-35.35%
Market Cap
$153.58M
Return on Equity (ROE)
N/A
TTM Avg
13.51%
3Y Avg
15.58%
5Y Avg
15.05%
Market Cap
$159.80M
Return on Equity (ROE)
N/A
TTM Avg
101.44%
3Y Avg
117.16%
5Y Avg
-25.56%
Market Cap
$156.22M
Return on Equity (ROE)
-14.07%
TTM Avg
-16.23%
3Y Avg
-27.66%
5Y Avg
-19.01%
Market Cap
$162.04M
Return on Equity (ROE)
-51.90%
TTM Avg
-23.95%
3Y Avg
-20.95%
5Y Avg
-18.62%
Market Cap
$154.32M
Return on Equity (ROE)
-170.49%
TTM Avg
-166.01%
3Y Avg
-121.36%
5Y Avg
-104.96%
Market Cap
$165.32M
Return on Equity (ROE)
3.51%
TTM Avg
-6.60%
3Y Avg
-9.04%
5Y Avg
-6.71%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LifeMD, Inc. (LFMDP) | $159.22M | -266.86% | -187.75% | -267.71% | -334.28% |
| PepGen Inc. (PEPG)vs › | $159.78M | -60.19% | -68.34% | -61.91% | -47.91% |
| Coherus Oncology, Inc. (CHRS)vs › | $159.14M | -215.26% | -150.35% | 8.65% | -35.35% |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $153.58M | N/A | 13.51% | 15.58% | 15.05% |
| Minerva Neurosciences, Inc. (NERV)vs › | $159.80M | N/A | 101.44% | 117.16% | -25.56% |
| Inogen, Inc. (INGN)vs › | $156.22M | -14.07% | -16.23% | -27.66% | -19.01% |
| Quanterix Corporation (QTRX)vs › | $162.04M | -51.90% | -23.95% | -20.95% | -18.62% |
| Neuronetics, Inc. (STIM)vs › | $154.32M | -170.49% | -166.01% | -121.36% | -104.96% |
| OptimizeRx Corp. (OPRX)vs › | $165.32M | 3.51% | -6.60% | -9.04% | -6.71% |
| Nkarta, Inc. (NKTX)vs › | $165.27M | -47.36% | -30.00% | -33.39% | -32.72% |
ROE
-266.9%
ROA
-35.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -266.86% |
| 2026-03-31 | -108.07% |
| 2025-12-31 | -25.88% |
| 2025-09-30 | -350.17% |
| 2023-12-31 | -587.56% |
| 2022-06-30 | -749.08% |
| 2022-03-31 | -359.78% |
| 2021-12-31 | -226.80% |
| 2019-03-31 | -625.84% |
| 2018-12-31 | -138.22% |
| 2018-09-30 | -59.70% |
| 2018-06-30 | -66.73% |
| 2018-03-31 | 41.12% |
| 2017-12-31 | -136.74% |
| 2017-09-30 | -196.34% |
| 2016-09-30 | -179.83% |
| 2016-06-30 | -109.50% |
| 2016-03-31 | -163.48% |
| 2015-12-31 | -61.94% |
| 2014-03-31 | -445.45% |
| 2013-12-31 | -137.23% |
| 2013-09-30 | -656.69% |
| 2013-06-30 | -159.77% |
| 2013-03-31 | -380.74% |
| 2012-12-31 | -330.10% |
